Skip to main content

Ocular Hypertension clinical trials at University of California Health

3 in progress, 1 open to eligible people

Showing trials for
  • 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

    open to eligible people ages 18 years and up

    Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

    at UCSD

  • Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

    Sorry, not yet accepting patients

    Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

    at UCSF

  • Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

    Sorry, accepting new patients by invitation only

    This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.

    at UCSD

Our lead scientists for Ocular Hypertension research studies include .

Last updated: